Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Given Consensus Rating of “Moderate Buy” by Analysts

Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) has been given an average recommendation of “Moderate Buy” by the five research firms that are presently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, three have given a buy rating and one has given a strong buy rating to the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $55.00.

SLN has been the subject of a number of research reports. HC Wainwright reiterated a “buy” rating and set a $75.00 target price on shares of Silence Therapeutics in a research report on Friday, March 13th. Jefferies Financial Group upgraded shares of Silence Therapeutics to a “strong-buy” rating in a research report on Wednesday, March 18th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Silence Therapeutics in a research report on Tuesday, April 21st. Finally, William Blair reiterated an “outperform” rating on shares of Silence Therapeutics in a research report on Monday, March 2nd.

Institutional Trading of Silence Therapeutics

Institutional investors have recently made changes to their positions in the stock. EHP Funds Inc. purchased a new stake in Silence Therapeutics in the third quarter worth $55,000. XTX Topco Ltd purchased a new stake in Silence Therapeutics in the fourth quarter worth $71,000. China Universal Asset Management Co. Ltd. lifted its stake in Silence Therapeutics by 65.9% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 13,653 shares of the company’s stock worth $83,000 after acquiring an additional 5,421 shares during the period. Citadel Advisors LLC purchased a new stake in Silence Therapeutics in the third quarter worth $112,000. Finally, Massar Capital Management LP purchased a new stake in Silence Therapeutics in the second quarter worth $115,000. Hedge funds and other institutional investors own 98.73% of the company’s stock.

Silence Therapeutics Stock Performance

Silence Therapeutics stock opened at $6.20 on Friday. The firm has a market cap of $292.89 million, a price-to-earnings ratio of -3.90 and a beta of 1.52. Silence Therapeutics has a 52-week low of $4.19 and a 52-week high of $8.40. The firm has a 50 day moving average price of $6.55 and a two-hundred day moving average price of $6.10.

Silence Therapeutics (NASDAQ:SLN) last announced its quarterly earnings data on Friday, May 8th. The company reported ($0.32) EPS for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.14). The firm had revenue of $0.42 million during the quarter, compared to analyst estimates of $1.26 million. Silence Therapeutics had a negative net margin of 8,943.86% and a negative return on equity of 105.34%. As a group, equities research analysts predict that Silence Therapeutics will post -1 EPS for the current fiscal year.

Silence Therapeutics Company Profile

Silence Therapeutics plc is a clinical-stage biotechnology company focused on the discovery and development of ribonucleic acid interference (RNAi) therapeutics. Leveraging its proprietary EnCore lipid nanoparticle delivery platform, the company aims to silence disease-causing genes in the liver and other tissues. Silence’s technology is designed to enhance targeted delivery of small interfering RNA (siRNA) molecules, with the goal of achieving durable therapeutic effects and improved safety profiles compared with traditional drug modalities.

The company’s lead product candidates include SLN360, an siRNA therapeutic designed to reduce lipoprotein(a) levels for cardiovascular risk reduction, and SLN124, aimed at treating hereditary hemochromatosis and beta-thalassemia by modulating iron metabolism.